Imiquimod in the treatment of lentigo maligna

Rajpar, S. F.; Marsden, Jerry

doi:10.1111/j.1365-2133.2006.07476.x

Cited by 91 publications

(78 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the case series, 4 4 of the 6 nonresponders showed no inflammation. In our opinion, the lack of clinical efficacy is most probably due to insufficient inflammatory reaction of the treated skin area.…”

Section: Inflammatorymentioning

confidence: 99%

“…Topical Tretinoin, Lung Cancer, and Lung-Related Mortality A mid continuing controversies over drug safety, 1,2 results of a trial of topical tretinoin-a commonly used medication for acne 3 and skin wrinkles, hyperpigmentation, and roughness 4 -raise serious concerns for the public health. The Veterans Affairs Topical Tretinoin Chemoprevention (VATTC) trial 5,6 was a vehicle-controlled randomized controlled trial (RCT) that studied whether topical tretinoin, 0.1%, cream applied to the face and ears could prevent nonmelanoma skin cancer.…”

Section: Comments and Opinionsmentioning

confidence: 99%

“…In a review of LM cases, 4 15 reports were found to describe the successful treatment of LM with imiquimod (11 case reports and 4 open-label studies). Taken together with the data reported herein, the response rates in the open-label studies ranged from 66% to 100%.…”

Section: Inflammatorymentioning

confidence: 99%

See 2 more Smart Citations

Imiquimod Treatment of Lentigo Maligna: An Open-Label Study of 34 Primary Lesions in 32 Patients

Buettiker¹,

Yawalkar²,

Braathen³

et al. 2008

Arch Dermatol

View full text Add to dashboard Cite

L entigo maligna (LM) is an in situ lesion with a 2% to 50% risk of progression to LM melanoma. 1 Currently, surgery or radiotherapy is usually recommended as the primary treatment for LM. In the literature, the recurrence rates reported for radiotherapy range from 0% to 19%, with a mean recurrence rate of approximately 7%; in addition, radiotherapy carries the risk of causing chronic radiodermatitis or radiation-induced malignant neoplasm. 2 A margincontrolled excision using "slow Mohs" (rush permanent sections) and Mohs micrographic surgery has the lowest recurrence rate, perhaps as low as 3%. 3Methods. Thirty-two patients with 34 histologically confirmed facial LM lesions were enrolled in an open-label trial of imiquimod, 5%, cream (Aldara; 3M Pharma, Rueschlikon, Switzerland). No patient had been treated

show abstract

Section: Inflammatorymentioning

confidence: 99%

Section: Comments and Opinionsmentioning

confidence: 99%

See 1 more Smart Citation

Imiquimod Treatment of Lentigo Maligna: An Open-Label Study of 34 Primary Lesions in 32 Patients

Buettiker¹,

Yawalkar²,

Braathen³

et al. 2008

Arch Dermatol

View full text Add to dashboard Cite

show abstract

“…A meta analysis published in 2006 identified a total of 11 case reports and 4 open-label studies, including a total of 67 lentigo maligna patients treated with topical imiquimod. Most patients experienced complete clinical remissions (Rajpar and Marsden, 2006). Immunohistological investigations revealed an increased infiltration of skin lesion with CD8+ cytotoxic T cells, suggesting that imiquimod was able to locally stimulate cellular immunity against premalignant melanocytes (Michalopoulos et al, 2004;Wolf et al, 2005).…”

Section: Synthetic Nucleic Acid Derivatives For Tumor Immunotherapy: mentioning

confidence: 98%

Toll-Like Receptor-Agonists in the Treatment of Skin Cancer: History, Current Developments and Future Prospects

Wenzel

Tormo

Tüting

2008

Toll-Like Receptors (TLRs) and Innate Immunity

View full text Add to dashboard Cite

This review will briefly cover some important aspects of skin structure and function before touching upon fundamental principles of neoplastic cell growth in the skin and some of the important molecular pathways involved. After presenting evidence for a role of the immune system in shaping the development of skin cancer, concepts for tumor immunotherapy with TLR-agonists are introduced from a historical point of view. Subsequently, the use of synthetic DNA, synthetic RNA and synthetic small immunostimulatory molecules for immunotherapy of early forms of epithelial carcinoma (actinic keratoses) and melanoma (lentigo maligna), as well as for advanced metastatic melanoma, is comprehensively presented. Finally, current developments and future prospects for immunotherapy of occult or unresectable melanoma metastastases, the most important clinical problem today, are discussed.

show abstract

“…Die topische Gabe Imiquimod besitzt sowohl antivirale als auch antitumoröse Eigenschaften Imiquimod besitzt sowohl antivirale als auch antitumoröse Eigenschaften Eine relativ neue Option ist der topische Einsatz von Immunmodulatoren von Imiquimod kann durch intraläsionale Gabe von IL-2 [45] und/oder IFN-α [22] ergänzt werden und zu einem besseren Ansprechen führen. Allerdings ist auf eine nicht zu vernachlässigende Anzahl an Therapieversagern und die Entwicklung von Lentigo-maligna-Melanomen bei der Behandlung der Lentigo maligna mit Imiquimod hinzuweisen [29]. Somit ist in der Anwendung große Vorsicht geboten, und weitere Studien sind abzuwarten.…”

Section: Epikutane Therapiemöglichkeitenunclassified

Therapie von Hautmetastasen beim malignen Melanom

et al. 2006

View full text Add to dashboard Cite

Malignant melanoma represents a particular challenge for dermatologists and oncologists because of its high and increasing incidence and the poor prognosis of patients with thick primary tumors (T3, T4). In advanced stages of melanoma, cutaneous and subcutaneous metastases have a special significance, as they markedly affect the patient and may lead to a limitation in quality of life. While topical therapy is possible, there are only limited clinical studies. The location, number, size and distribution of skin metastases, involvement of internal organs, age and general condition should be considered in assessing therapeutic options. Especially with solitary, easily accessible metastases, surgical excision represents the therapy of choice. Ablation using CO(2) laser is an alternative. With extensive metastases in just one extremity, isolated limb perfusion (ILP) with melphalan is an option, while multiple, smaller metastases can be irradiated. Further, several chemotherapeutic agents and immune modulators can be used topically, peri- and intralesionally.

show abstract

Imiquimod in the treatment of lentigo maligna

Abstract: Although imiquimod clearly has an effect on LM, this analysis of available studies has helped to identify concerns about its use. Without controlled evidence and prolonged follow up, the use of imiquimod for LM must still be considered experimental.

Cited by 91 publications

References 33 publications

Imiquimod Treatment of Lentigo Maligna: An Open-Label Study of 34 Primary Lesions in 32 Patients

Imiquimod Treatment of Lentigo Maligna: An Open-Label Study of 34 Primary Lesions in 32 Patients

Toll-Like Receptor-Agonists in the Treatment of Skin Cancer: History, Current Developments and Future Prospects

Therapie von Hautmetastasen beim malignen Melanom

Contact Info

Product

Resources

About